Literature DB >> 7468414

Relationship of ventricular ectopy in men without apparent heart disease to occurrence of ischemic heart disease and sudden death.

S W Rabkin, F A Mathewson, R B Tate.   

Abstract

The purpose of this investigation was to determine whether ventricular ectopic beats, or ventricular premature beats (VPBs), on routine electrocardiograms in men without apparent heart disease predict the later occurrence of clinical manifestations of ischemic heart disease (IHD). The Manitoba Study cohort consisted of 3983 men predominantly between 25 and 34 years of age and free of IHD at entry. During the 29-year observation period, 401 persons without clinical evidence of heart disease had VPBs on an electrocardiogram at a routine examination. They were followed 10.8 +/- 0.5 (SEM) years and 13.5% (54 men) later manifested IHD. Age-specific total IHD incidence was significantly (p less than 0.05) greater for men 40 to 59 years of age at VPB occurrence compared to men of the same age without VPBs. The clinical manifestation with the strongest association with VPBs was sudden death. VPB characteristics of frequency, configuration, coupling interval, and postextrasystolic T-wave change did not distinguish those who developed IHD. Prematurity index (R-R'/QT) showed a trend toward an association of late coupled ectopic beats (R-R'/QT greater than 1.6) and IHD risk. However, faster basic ventricular rate plus VPBs significantly correlated with greater IHD probability. Thus ventricular ectopic beats on a routine electrocardiogram in men over 40 years of age without apparent heart disease identify those at high risk for a clinical IHD event, especially sudden death.

Entities:  

Mesh:

Year:  1981        PMID: 7468414     DOI: 10.1016/0002-8703(81)90655-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

Review 1.  Antiarrhythmic therapies for the prevention of sudden cardiac death.

Authors:  F A McAlister; K K Teo
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Sudden unexpected cardiac death as a function of time since the detection of electrocardiographic and clinical risk factors in apparently healthy men: the Manitoba Follow-Up Study, 1948 to 2004.

Authors:  T Edward Cuddy; Robert B Tate
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

3.  Prognostic significance of PVCs and resting heart rate.

Authors:  Gregory Engel; Shaun Cho; Afshin Ghayoumi; Takuya Yamazaki; Sung Chun; William F Fearon; Victor F Froelicher
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

4.  High burden of premature ventricular contractions in structurally normal hearts: To worry or not in pediatric patients?

Authors:  Nandita Sharma; Daniel Cortez; Jason R Imundo
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-06-14       Impact factor: 1.468

5.  The electrocardiogram in apparently healthy men and the risk of sudden death.

Authors:  S W Rabkin; F L Mathewson; R B Tate
Journal:  Br Heart J       Date:  1982-06

6.  Diuretics and arrhythmias in the Medical Research Council trial.

Authors:  P K Whelton
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

7.  Arrhythmia risk stratification based on QT interval instability: an intracardiac electrocardiogram study.

Authors:  Xiaozhong Chen; Larisa G Tereshchenko; Ronald D Berger; Natalia A Trayanova
Journal:  Heart Rhythm       Date:  2013-02-13       Impact factor: 6.343

Review 8.  Electrolyte abnormalities and ventricular arrhythmias.

Authors:  P V Caralis; E Perez-Stable
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Propafenone for the treatment of severe ventricular arrhythmias.

Authors:  S W Rabkin; C E Rotem; K Boroomand-Rashti; B Bar-Shlomo
Journal:  Can Med Assoc J       Date:  1984-09-15       Impact factor: 8.262

10.  Electrocardiographic abnormalities in apparently healthy men and the risk of sudden death.

Authors:  S W Rabkin
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.